Navigating Multimodality Therapy in Non–Small Cell Lung Cancer: Neoadjuvant-Only Versus Perioperative Immunotherapy, Surgical Imperatives, and Future Approaches
American Society of Clinical Oncology Educational Book · 2026
DOI: 10.1200/edbk-26-519336 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026. Verfasst von Gökce Yavuz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic and Upper Gastrointestinal Surgery, McGill University Health Centre, Montreal, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 126 Literaturangaben.
Abstract (Originalsprache)
Neoadjuvant and perioperative immunotherapy have redefined the treatment landscape for select patients with early-stage and locally-advanced resectable non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis combined with platinum-based chemotherapy have achieved substantially higher rates of pathologic complete response and major pathologic response than chemotherapy alone, translating into meaningful improvements in event-free survival and, in select trials, overall survival. Despite this progress, several clinically important questions remain unanswered, including the relative value of neoadjuvant versus perioperative approaches, the optimal sequencing and duration of therapy, and how best to tailor treatment according to tumor biology, host features, and risk of disease recurrence. Emerging biomarkers such as PD-L1 expression, circulating tumor DNA dynamics, and pathologic response may help refine treatment selection although their role in routine decision making is still evolving. The integration of immunotherapy into curative-intent treatment also has important multidisciplinary implications. Accurate staging, appropriate biomarker testing, thoughtful considerations for multimodal therapy integration throughout the perioperative setting, high-quality surgical resection, and careful response assessment remain essential to maximize the benefit of systemic therapy. This review summarizes the current evidence supporting neoadjuvant and perioperative immunotherapy in resectable NSCLC and discusses key biomarkers, unresolved clinical questions, and the practical implications for multidisciplinary care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Thoracic and Upper Gastrointestinal Surgery, McGill University Health Centre, Montreal, Canada.
- Department of Thoracic/Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Thoracic Surgical Oncology Service, Instituto Nacional de Cancerología, México City, Mexico.
ORCID-Profile: José Francisco Corona-Cruz
Zitieren
APA
Yavuz, G., Wang, M., Spicer, J. D., Cascone, T., & Corona-Cruz, J. F. (2026). Navigating Multimodality Therapy in Non–Small Cell Lung Cancer: Neoadjuvant-Only Versus Perioperative Immunotherapy, Surgical Imperatives, and Future Approaches. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk-26-519336
Vancouver
Yavuz G, Wang M, Spicer JD, Cascone T, Corona-Cruz JF. Navigating Multimodality Therapy in Non–Small Cell Lung Cancer: Neoadjuvant-Only Versus Perioperative Immunotherapy, Surgical Imperatives, and Future Approaches. American Society of Clinical Oncology Educational Book. 2026. doi:10.1200/edbk-26-519336
BibTeX
@article{Yavuz2026,
author = {Yavuz, Gökce and Wang, Michael and Spicer, Jonathan D and Cascone, Tina and Corona-Cruz, José Francisco},
title = {Navigating Multimodality Therapy in Non–Small Cell Lung Cancer: Neoadjuvant-Only Versus Perioperative Immunotherapy, Surgical Imperatives, and Future Approaches},
journal = {American Society of Clinical Oncology Educational Book},
year = {2026},
doi = {10.1200/edbk-26-519336}
}
EUVIMED